Review



h22 mouse liver cancer cell‐specific neoantigen (sequence: htdahaqafaalfdsmh)  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation h22 mouse liver cancer cell‐specific neoantigen (sequence: htdahaqafaalfdsmh)
    Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC <t>neoantigen</t> nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.
    H22 Mouse Liver Cancer Cell‐Specific Neoantigen (Sequence: Htdahaqafaalfdsmh), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/h22+mouse+liver+cancer+cell+specific+neoantigen+(sequence%3A+htdahaqafaalfdsmh)/h22+mouse+liver+cancer+cell+specific+neoantigen++sequence++htdahaqafaalfdsmh+/pmc09009112-156-5-11
    Average 90 stars, based on 1 article reviews
    h22 mouse liver cancer cell‐specific neoantigen (sequence: htdahaqafaalfdsmh) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine Efficiency"

    Article Title: Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine Efficiency

    Journal: Advanced Science

    doi: 10.1002/advs.202105631

    Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC neoantigen nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.
    Figure Legend Snippet: Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC neoantigen nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.

    Techniques Used: Immunopeptidomics, In Silico, Enzyme-linked Immunospot, Vaccines, Activation Assay

    Characterization of mD@cSMN nano‐vaccines. A) Schematic illustration of the preparation of mD@cSMN nano‐vaccines. B) TEM image of SMN photosensitizers and the size distribution of SMNs (insert picture). C) The absorbance of DPBF after decomposition by generated 1 O 2 from SMN with and without D) 670 nm laser irradiation (50 mW cm −2 ) for different times. E) The normalized absorbance of DPBF at 415 nm after decomposition by ROS generation in SMNs with or without irradiation for different times and the DPBF without SMN is used as the control. F) The maturation of BMDCs after co‐incubation with PBS or H22 tumor cell‐specific neoantigen for 72 h, respectively, which are analyzed by FACS with staining CD80 and CD86 antibodies. G) The TEM image of mD@cSMN nano‐vaccines and their size distribution (insert picture). H) The surface zeta potential of the SMNs, SMNs‐NH 2 , Fe‐SMNs, cSMNs, the mature DCs membrane, and mD@cSMNs, ( n = 3). I) The protein pattern analysis of matured DCs membrane and mD@cSMNs through SDS‐PAGE (coomassie blue staining). J) Western blotting analysis of membrane‐specific protein markers. The samples are run at equal protein amounts and blotted with CD80, CD86, and MHC‐II antibodies. K) The cumulative captopril release kinetics from mD@cSMNs in different pH conditions within 20 h.
    Figure Legend Snippet: Characterization of mD@cSMN nano‐vaccines. A) Schematic illustration of the preparation of mD@cSMN nano‐vaccines. B) TEM image of SMN photosensitizers and the size distribution of SMNs (insert picture). C) The absorbance of DPBF after decomposition by generated 1 O 2 from SMN with and without D) 670 nm laser irradiation (50 mW cm −2 ) for different times. E) The normalized absorbance of DPBF at 415 nm after decomposition by ROS generation in SMNs with or without irradiation for different times and the DPBF without SMN is used as the control. F) The maturation of BMDCs after co‐incubation with PBS or H22 tumor cell‐specific neoantigen for 72 h, respectively, which are analyzed by FACS with staining CD80 and CD86 antibodies. G) The TEM image of mD@cSMN nano‐vaccines and their size distribution (insert picture). H) The surface zeta potential of the SMNs, SMNs‐NH 2 , Fe‐SMNs, cSMNs, the mature DCs membrane, and mD@cSMNs, ( n = 3). I) The protein pattern analysis of matured DCs membrane and mD@cSMNs through SDS‐PAGE (coomassie blue staining). J) Western blotting analysis of membrane‐specific protein markers. The samples are run at equal protein amounts and blotted with CD80, CD86, and MHC‐II antibodies. K) The cumulative captopril release kinetics from mD@cSMNs in different pH conditions within 20 h.

    Techniques Used: Vaccines, Generated, Irradiation, Control, Incubation, Staining, Zeta Potential Analyzer, Membrane, SDS Page, Western Blot



    Similar Products

    h22 mouse liver cancer cell‐specific neoantigen (sequence: htdahaqafaalfdsmh)  (GenScript corporation)
    90
    GenScript corporation h22 mouse liver cancer cell‐specific neoantigen (sequence: htdahaqafaalfdsmh)
    Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC <t>neoantigen</t> nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.
    H22 Mouse Liver Cancer Cell‐Specific Neoantigen (Sequence: Htdahaqafaalfdsmh), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/h22+mouse+liver+cancer+cell+specific+neoantigen+(sequence%3A+htdahaqafaalfdsmh)/h22+mouse+liver+cancer+cell+specific+neoantigen++sequence++htdahaqafaalfdsmh+/pmc09009112-156-5-11
    Average 90 stars, based on 1 article reviews
    h22 mouse liver cancer cell‐specific neoantigen (sequence: htdahaqafaalfdsmh) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC neoantigen nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.

    Journal: Advanced Science

    Article Title: Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine Efficiency

    doi: 10.1002/advs.202105631

    Figure Lengend Snippet: Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC neoantigen nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.

    Article Snippet: H22 mouse liver cancer cell‐specific neoantigen (sequence: HTDAHAQAFAALFDSMH) was obtained from GenScript USA Inc.

    Techniques: Immunopeptidomics, In Silico, Enzyme-linked Immunospot, Vaccines, Activation Assay

    Characterization of mD@cSMN nano‐vaccines. A) Schematic illustration of the preparation of mD@cSMN nano‐vaccines. B) TEM image of SMN photosensitizers and the size distribution of SMNs (insert picture). C) The absorbance of DPBF after decomposition by generated 1 O 2 from SMN with and without D) 670 nm laser irradiation (50 mW cm −2 ) for different times. E) The normalized absorbance of DPBF at 415 nm after decomposition by ROS generation in SMNs with or without irradiation for different times and the DPBF without SMN is used as the control. F) The maturation of BMDCs after co‐incubation with PBS or H22 tumor cell‐specific neoantigen for 72 h, respectively, which are analyzed by FACS with staining CD80 and CD86 antibodies. G) The TEM image of mD@cSMN nano‐vaccines and their size distribution (insert picture). H) The surface zeta potential of the SMNs, SMNs‐NH 2 , Fe‐SMNs, cSMNs, the mature DCs membrane, and mD@cSMNs, ( n = 3). I) The protein pattern analysis of matured DCs membrane and mD@cSMNs through SDS‐PAGE (coomassie blue staining). J) Western blotting analysis of membrane‐specific protein markers. The samples are run at equal protein amounts and blotted with CD80, CD86, and MHC‐II antibodies. K) The cumulative captopril release kinetics from mD@cSMNs in different pH conditions within 20 h.

    Journal: Advanced Science

    Article Title: Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine Efficiency

    doi: 10.1002/advs.202105631

    Figure Lengend Snippet: Characterization of mD@cSMN nano‐vaccines. A) Schematic illustration of the preparation of mD@cSMN nano‐vaccines. B) TEM image of SMN photosensitizers and the size distribution of SMNs (insert picture). C) The absorbance of DPBF after decomposition by generated 1 O 2 from SMN with and without D) 670 nm laser irradiation (50 mW cm −2 ) for different times. E) The normalized absorbance of DPBF at 415 nm after decomposition by ROS generation in SMNs with or without irradiation for different times and the DPBF without SMN is used as the control. F) The maturation of BMDCs after co‐incubation with PBS or H22 tumor cell‐specific neoantigen for 72 h, respectively, which are analyzed by FACS with staining CD80 and CD86 antibodies. G) The TEM image of mD@cSMN nano‐vaccines and their size distribution (insert picture). H) The surface zeta potential of the SMNs, SMNs‐NH 2 , Fe‐SMNs, cSMNs, the mature DCs membrane, and mD@cSMNs, ( n = 3). I) The protein pattern analysis of matured DCs membrane and mD@cSMNs through SDS‐PAGE (coomassie blue staining). J) Western blotting analysis of membrane‐specific protein markers. The samples are run at equal protein amounts and blotted with CD80, CD86, and MHC‐II antibodies. K) The cumulative captopril release kinetics from mD@cSMNs in different pH conditions within 20 h.

    Article Snippet: H22 mouse liver cancer cell‐specific neoantigen (sequence: HTDAHAQAFAALFDSMH) was obtained from GenScript USA Inc.

    Techniques: Vaccines, Generated, Irradiation, Control, Incubation, Staining, Zeta Potential Analyzer, Membrane, SDS Page, Western Blot